At last year’s Orthopedic Research Society conference on tendon diseases, held at the Mayo Clinic in the United States, a scientific abstract by Anna Gosiewska et al. was presented, highlighting a method of innovative treatment of tendon injuries using non-cellular placenta preparations.
According to comments from experts of Celularity, the company developing these technologies, tendon injuries associated with sports, excessive load or degenerative diseases pose significant problems in both treatment and recovery of patients. In 2022, global spending on the treatment of tendon diseases amounted to 2.3 billion US dollars, and by 2032, according to experts, this parameter will reach 4.8 billion US dollars.
Decellularized placenta is a rich source of natural extracellular matrix, which, according to experts, is beneficial for tissue repair and regeneration. Based on this biomaterial, Celularity is developing advanced therapeutic solutions specifically for tendon injuries. It is expected that innovative technologies using decellularized placental biomaterials will become a new approach in the treatment of tendon injuries and can give both patients and healthcare professionals new hope for improving treatment outcomes and improving the quality of life of patients.
The results of the study described in the abstract provide insight into the in vivo evaluation of Celularity decellularized placental biomaterials in two clinically relevant models. The results of the studies demonstrate faster healing in the placental treatment group and complete incorporation of placental tissue into the tendon within three months after implantation. Therefore, decellularized human placenta biomaterials can be considered as a promising matrix suitable for the treatment and healing of tendon injuries.
Source: https://celularity.com/celularity-abstract-emerging-technologies-for-the-management-and-protection-of-tendon-injuries-decellularized-placental-biomaterials-accepted-at-ors-tendon-conference-2024/; https://www.biospace.com/celularity-abstract-emerging-technologies-for-the-management-and-protection-of-tendon-injuries-decellularized-placental-biomaterials-accepted-at-ors-tendon-conference-2024?s=110
In Ukraine, the Institute of Cell Therapy, along with the service of storing stem cells of umbilical cord blood and umbilical cord, provides future parents with the opportunity to preserve the placenta collected during childbirth in accordance with international standards and requirements of the Ministry of Health of Ukraine. The safety and effectiveness of cellular and non-cellular preparations prepared from the placenta by the Cryobank of the Institute of Cell Therapy have been confirmed by clinical studies based on leading state scientific and academic medical institutions (more https://csict.com.ua/rnd-research-articles/efficiency-of-the-cryopreserved-allogeneic-amniotic-membrane-transplantation-in-patients-with-infectious-and-neurotrophic-keratitis/?lang=uk та https://csict.com.ua/rnd-research-articles/оцінка-ефективності-застосування-ме/?lang=uk). In 2017, for the first time in the world, placental stem cells cryopreserved by the Cryobank of the Institute of Cell Therapy were injected into the heart during coronary artery bypass grafting surgery at the State Institution “Institute of Cardiovascular Surgery named after M.M. Amosov of the Academy of Medical Sciences” with high clinical effectiveness (https://stemcellbank.org.ua/vpervye-v-mire-stvolovye-kletki-placenty-obrabotannye-v-ikt-vosstanovili-beznadezhno-porazhennoe-serdce/)
